Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2008
Industry: Medical Technology (Medical supplies, devices, laboratory equipment, and diagnostic products)
BD operates through three worldwide segments: BD Medical (injection, infusion, and surgery products), BD Diagnostics (specimen collection and infectious disease testing), and BD Biosciences (research and clinical tools). The company employs 28,277 people globally, with significant operations in the U.S. and international markets including Europe, Asia Pacific, and Latin America.
Key Financial Metrics
Note: Specific revenue, profit, and cash flow totals for the fiscal year are incorporated by reference to Exhibit 13 (Annual Report to Shareholders) and are not explicitly stated in the provided text. The following metrics are available from the filing text:
- Research & Development (R&D) Spend: $396 million for fiscal 2008 (compared to $360 million in 2007 and $302 million in 2006).
- Acquired In-Process R&D Charges: None reported for 2008 (Previous years included $122 million in 2007 and $53 million in 2006).
- Stock Repurchases (Q4 2008): 1,119,884 shares purchased at an average price of $85.85 per share.
- Valuation and Qualifying Accounts (Allowance for Doubtful Accounts): Ending balance of $26.7 million as of September 30, 2008.
- Market Capitalization (Non-Affiliate): Approximately $20.9 billion as of March 31, 2008.
- Outstanding Shares: 243,115,261 shares as of October 31, 2008.
Material Changes and Operational Updates
- Acquisition: On May 12, 2008, BD acquired 100% of Cytopeia Inc., a developer of advanced flow cytometry cell sorting instruments, to strengthen its position in cell therapy and stem cell research.
- Regulatory Resolution: The FDA closed out a warning letter issued in November 2006 regarding the San Lorenzo, Puerto Rico facility after BD implemented a corrective action plan satisfactory to the agency in fiscal 2008.
- UN Suspension: In May 2008, BD's Swiss subsidiary was suspended from the UN Secretariat Procurement Division's vendor roster for a minimum of six months due to an investigation into the Oil-for-Food Programme. BD maintains it made no improper payments and is seeking review of the suspension.
- Executive Changes: John R. Considine was appointed Vice Chairman and Chief Financial Officer in March 2008.
Guidance, Risks, and Contingencies
Management Commentary and Outlook: BD notes that while current economic conditions and financial market disruptions have not yet impaired operations, there is no assurance they will not do so in the future. The company anticipates potential decreases in demand, longer sales cycles, and increased price competition due to the economic downturn.
Key Risks:
- Economic Conditions: Potential adverse effects from global financial market disruption, credit availability, and reduced healthcare spending.
- Foreign Currency: Over half of fiscal 2008 revenues were international; volatility in exchange rates poses a significant risk.
- Raw Materials: Reliance on sole suppliers for certain materials (primarily resins and components for BD Biosciences) creates supply chain vulnerability.
- Reimbursement: Changes in third-party payer policies (governmental and private) could negatively impact product pricing and demand.
- Competition: Increased pricing pressure from low-cost manufacturing locations (e.g., China) and new entrants.
Legal Proceedings: BD is a defendant in multiple significant lawsuits, including:
- Antitrust Litigation: Consolidated class actions alleging violations of federal antitrust laws regarding pricing of hypodermic products.
- Patent Disputes: Lawsuits filed by Retractable Technologies, Inc. (RTI) alleging patent infringement regarding BD Integra syringes; trial scheduled for March 2009.
- Product Liability: Pending suits regarding accidental needlesticks and historical litigation regarding natural rubber latex gloves (ceased manufacturing in 1995).
- False Claims Act: A qui tam complaint alleging inflated healthcare reimbursement costs via group purchasing organizations.
Investor Verification Checklist
- Verify the full consolidated financial statements (Revenue, Net Income, Cash Flow) in Exhibit 13, as specific totals are not in the main text.
- Monitor the outcome of the Retractable Technologies, Inc. patent trial scheduled for March 2009.
- Assess the impact of the UN vendor suspension on BD's international government contracts.
- Review the "Financial Review" section in Exhibit 13 for detailed segment performance and foreign currency impact analysis.
- Track the status of the antitrust class action litigation consolidated in New Jersey.